PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT), a pioneering clinical-stage biotechnology company, has made a significant announcement regarding its latest financial move aimed at bolstering its innovative cancer therapies. Today, the Company revealed the pricing details of an underwritten public offering comprising 3,066,666 units, which includes 399,999 units sold following the full exercise of the underwriters option to purchase additional units.

Each unit of this offering consists of one common share (or a pre-funded warrant in lieu thereof) along with one warrant, commonly referred to as the Warrants. Each unit is being offered to the public at a price of $4.50, which includes the exercise price for the Pre-Funded Warrant. The Company anticipates gross proceeds of approximately $13.8 million from this public offering before any deductions for underwriting discounts or offering expenses.

Excitingly, the Warrants bundled within the units have received approval for listing on the Nasdaq Capital Market and are expected to begin trading under the symbol BCTXZ starting April 25, 2025. Each Warrant is immediately exercisable and grants holders the right to purchase one common share at an exercise price of $5.25 per share, with an expiration period of five years from the issuance date. It is important to note that the common shares (or Pre-Funded Warrants) and Warrants can only be purchased together as part of this offering, although they will be issued separately.

The anticipated closing date for this offering is set for April 28, 2025, pending the fulfillment of standard closing conditions. In this transaction, BriaCell is utilizing the exemption outlined in Section 602.1 of the TSX Company Manual. This exemption allows the TSX to forgo its usual standards for certain transactions involving eligible interlisted issuers listed on recognized exchanges like Nasdaq.

BriaCell plans to allocate the net proceeds from this offering primarily towards fulfilling working capital requirements, supporting general corporate activities, and advancing various business objectives that are crucial for the Companys growth.

ThinkEquity has been appointed as the sole book-running manager for this public offering, illustrating the confidence in BriaCells strategic direction.

Additionally, a registration statement on Form S-1 (File No. 333-286670) pertaining to these securities was filed with the Securities and Exchange Commission (SEC) and received effective status on April 24, 2025. This public offering is being conducted solely via a prospectus. Interested parties may obtain copies of the final prospectus from ThinkEquity, located at 17 State Street, 41st Floor, New York, New York 10004. The final prospectus will also be submitted with the SEC and will be accessible on the SEC's website at

Mei-Ling Chen